Avid Bioservices Inc (CDMO)

[cjgaddy]

I wonder what spurred Dana-Farber/Harvard’s Dr. Kathleen Mahoney (or co-authors Dr. Gordon Freeman/Harvard / Paul Rennert/Consultant) to add this to her new Nature-Reviews article on Combination Cancer Immunotherapy:

Pg19: “Bavituximab might also be beneficial when paired with a targeted therapy such as the VEGFR2-specific antibody ramucirumab (Cyramzain, developed by Eli Lilly & Co.), which has reported positive Phase III trial data as 2nd-Line therapy in combination with docetaxel for NSCLC.

I’d love to know if it just a simple observation she came up with on her own, or whether someone else provided input.

= = = = = = = = = = = =
NATURE REVIEWS Drug Discovery (series: Cancer Immunotherapy)
Aug. 2015 (Pub. online: 7-31-15)
“Combination Cancer Immunotherapy & New Immunomodulatory Targets”
KATHLEEN M. MAHONEY, Paul D. Rennert, Gordon J. Freeman
Dana–Farber Cancer Institute, Harvard Medical School, Dept of Medical Oncology, Boston
http://www.nature.com/nrd/journal/v14/n8/abs/nrd4591.html
PDF: http://www.sugarconebiotech.com/wp/wp-content/uploads/2015/07/nrd4591-1.pdf
- - - - - - -
Note: On 12-12-14, the FDA approved Eli Lilly’s ramucirumab (trade name Cyramzain) combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-containing chemotherapy.
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm

• K.Mahoney: http://www.conquercancerfoundation.org/kathleen-m-mahoney-md-phd
• G.Freeman: http://www.dfhcc.harvard.edu/insider/member-detail/member/gordon-j-freeman-phd
• Paul Rennert: http://www.sugarconebiotech.com/?author=2 (SugarCone Biotech “A consortium managed by Paul D Rennert, a well-known and highly respected biotechnology scientist. Consortium members are highly skilled and experienced professionals from the biotechnology sector…Our core strength is Strategic Analysis and Consulting to support successful corporate development. We engage with our clients in academic technology transfer, start-up creation and financing, corporate in-licensing, due diligence, competitive intelligence, program development and execution, outsourcing and vendor selection, out-licensing, defining critical transition stages and milestones, and identifying academic and corporate partnerships.”)